My research focuses on developing new and effective treatments for Alzheimer's disease as well as studying the cognitive and behavioral disturbances seen in mild cognitive impairment and early dementia. Our center is a major national site for clinical trials of experimental drugs for the treatment of Alzheimer's disease, including research on biomarkers of preclinical disease and secondary prevention approaches.

Alzheimer's disease is one of the most important health problems facing our aging population today. The cognitive decline and behavioral problems posed by Alzheimer's disease and related dementia disorders produce not only substantial morbidity and mortality for the affected patients, but also a major socioeconomic burden for family caregivers and the community at large.

Mild cognitive impairment is increasingly recognized as a prodrome to dementia, usually of the Alzheimer type. A major emphasis of our research is to define the cognitive and behavioral changes that occur during the prodromal stage of dementia called mild cognitive impairment. We are a site for the Alzheimer's Disease Neuroimaging Initiative, a multicenter study funded by NIH, which seeks to define the earliest physical changes in the brain of persons with Alzheimer's disease using advanced neuroimaging techniques.

Among the many important behavioral problems seen in the early stages of Alzheimer's disease is driving impairment. Currently we are examining the longitudinal effects of dementia on driving abilities in the elderly, using naturalistic recording techniques, in the hopes of developing a computerized screening test for hazardous driving due to such cognitive impairment, as well as early interventions to propmote safe driving.

Our research also focuses on developing new and effective treatments for Alzheimer's disease. Our center is a major site for multicenter clinical trials of experimental drugs for the treatment of Alzheimer's disease, including studies that led to the approval of tacrine and donepezil, the first two medications approved for the treatment of Alzheimer's disease, and memantine, the latest medication approved for treatment. More recently we are focusing on research defining biomarkers of preclinical Alzheimer's disease, i.e., the earliest stage of Alzheimer's in which there are developing pathologic changes in the brain yet no symptoms of significant cognitive impairment or dementia.  In the hope of finding a treatment that could delay the onset of dementia, we are particpating in highly innovative clinical trials aimed at secondary prevention for those in the preclinical stage of disease.

GRANTS & CLINICAL RESEARCH:

1.  #970-26                                                                                                                           1990-1994

Parke-Davis Pharmaceutical Co.

Double-blind, placebo-controlled, parallel group, multicenter study of tacrine in Alzheimer's disease patients.

This study is to determine safety and efficacy of tacrine for the treatment of Alzheimer’s disease. (phase III)

Role: Site PI

 

2.  #996-019/025                                                                                                                 1991-1993

DuPont Merck Pharmaceutical Co.

Randomized placebo-controlled study of DUP-996 (linopirdine) in patients with mild to moderate dementia of the Alzheimer type.

This study is to determine safety and efficacy of linopirdine for the treatment of Alzheimer’s disease. (phase II)

Role: Site PI

 

3.  Surdna Foundation Grant                                            Ott (PI)                                   1991-1993

Brown University Center for Gerontology and Health Care Research

Awareness of deficit in Alzheimer's disease.

This study is to examine the psychological and physiological substrate of deficit awareness in patients with Alzheimer’s disease.

Role: PI

 

4.  #303                                                                                                                                 1993-1994

Hoechst-Roussel Pharmaceuticals, Inc.

Multicenter, 24-week, double-blind, parallel group safety, tolerance and efficacy comparison of placebo and HP 029 (velnacrine maleate) in outpatients with Alzheimer's disease.

This study is to determine safety and efficacy of velnacrine for the treatment of Alzheimer’s disease. (phase II)

Role: Site PI

 

5.  #159-103                                                                                                                         1994-1996

Pfizer, Inc.            

A randomized, double-blind, placebo-controlled study of the safety and efficacy of three doses of CP-118,954 administered for 12 weeks to subjects with Alzheimer's disease.     

This study is to determine safety and efficacy of CP-118,954 for the treatment of Alzheimer’s disease. (phase II)

Role: Site PI

 

6.  #D94-029                                                                                                                        1995-1998

Miles/Bayer Inc.

A double blind, placebo-controlled, multicenter pilot study to evaluate the safety and tolerability of metrifonate in patients with probable Alzheimer's disease (phase II)

This study is to determine safety and efficacy of metrifonate for the treatment of Alzheimer’s disease. (phase II)

Role: Site PI

 

7.  #D95-018                                                                                                                        1995-1998

Bayer Corp.

A double blind, placebo controlled trial to evaluate the safety and efficacy of metrifonate (BAY A 9826) in patients

with probable Alzheimer's disease.  

This study is to determine safety and efficacy of metrifonate for the treatment of Alzheimer’s disease. (phase III)

Role: Site PI

 

8.  #E2020-A001-312                                                                                                         1996-1997

Eisai America, Inc.

A 54-week, randomized, double-blind, placebo-controlled evaluation of the effects of donepezil hydrochloride (E2020) on functional outcomes in patients with Alzheimer's disease with a staged crossover to open-label donepezil hydrochloride.

This study is to determine safety and efficacy of donepezil for the treatment of Alzheimer’s disease. (phase IIIB)

Role: Site PI                         

 

9.  UO1 #AG10483                                             Leon Thal (PI)                                      1996-1998

NIH/NIA/ADCS                                                  Mulnard (Project director)

A multicenter, double-blind, placebo-controlled study of estrogen replacement therapy in patients with mild to moderate Alzheimer's disease: A pilot study of the Alzheimer's Disease Cooperative Study (ADCS).

This study is to determine safety and efficacy of estrogen for the treatment of Alzheimer’s disease. (phase II)

Role: Site PI                                                         

                                                                               

11.  # CV-2619/PNFP-001                                                                                                 1997-1999

Takeda America, Inc.

A randomized, double-blind, placebo-controlled, twelve-month safety and efficacy trial of 120, 240, and 360 mg tid of Idebenone (CV-2619) in patients with probable Alzheimer's disease.

This study is to determine safety and efficacy of donepezil for the treatment of Alzheimer’s disease. (phase III)

Role: Site PI         

 

12. BAY a 9826/D97-019                                                                                                 1997-1998

Bayer Corp.

Metrifonate investigational nationwide trial.

This study is to determine safety and efficacy of metrifonate for the treatment of Alzheimer’s disease. (phase IIIB)

Role: Site PI

 

13. U01 #AG10483                                             Thal (PI)                                                1998-2000

NIH/NIA/ADCS                                                  Singer (Project director)

A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer’s disease.

This study is to determine safety and efficacy of melatonin for the treatment of sleep disturbance in Alzheimer’s disease. (phase IV)

Role: Site PI

 

14. #FA-960-0002                                                                                                               1999-2000

Fujisawa Research Institute of America

A randomized, double-blind, placebo-controlled study to determine the safety and efficacy of FK960 in patients with mild to moderate probable Alzheimer’s disease.

This study is to determine safety and efficacy of FK960 for the treatment of Alzheimer’s disease. (phase II)

Role: Site PI         

 

15. #082-99-003                                                                                                                  1999-2000

NeoTherapeutics, Inc.

A multicenter, randomized, double-blind, placebo-controlled study to evaluate AIT-082 in patients with probable Alzheimer’s disease of mild to moderate severity.

This study is to determine safety and efficacy of FK960 for the treatment of Alzheimer’s disease. (phase II)              

Role: Site PI         

 

16. PRG-1837                                                      Cahn-Weiner (PI)                                                10/1/99-12/31/01

Alzheimer’s Association                                    

Combined behavioral and pharmacologic intervention to improve memory in Alzheimer’s disease.

This study is to determine the efficacy of a memory training program for patients with mild Alzheimer’s disease.

Role: Co-investigator         

 

17. U01 #AG10483                                             Thal (PI)                                                1999-2001

NIH/NIA/ADCS                                                  Aisen (Project director)

A multicenter trial of rofecoxib and naproxen in Alzheimer’s disease.

This study is to determine safety and efficacy of non-steroidal anti-inflammatory drugs for the treatment of Alzheimer’s disease. (Phase IIB)       

Role: Site PI         

 

 

 

18. #082-2001-001                                                                                                             2001-2002

NeoTherapeutics, Inc.

A placebo-controlled dose-titration efficacy and tolerability study of Neotrofin^TM in patients with probable Alzheimer’s disease.

This study is to determine safety and efficacy of Neotrofin for the treatment of Alzheimer’s disease. (Phase IIB)

Role: Site PI         

 

19. IRG-99-1668                                                 Stern (PI)                                               7/1/99-1/31/03

Alzheimer’s Association                    

A double-blind study of donepezil with and without thyroid hormone in the treatment of Alzheimer’s dementia.

This study is to determine safety and efficacy of low dosage thyroid hormone for the treatment of Alzheimer’s disease. (Phase II)

Role: Consultant

 

20. U01 #AG10483                                             Thal (PI)                                                1998-2003

NIH/NIA/ADCS                                                  Peterson (Project director)

A randomized, double-blind, placebo-controlled trial of vitamin E and Aricept to prevent clinical progression from mild cognitive impairment (MCI) to Alzheimer’s Disease (AD).

This study is to determine safety and efficacy of donepezil and vitamin E in preventing conversion to dementia among subjects with mild cognitive impairment. (Phase III)

Role: Site PI         

 

21. NO1 #WH-32119                                         Shumaker (PI)                                      6/1/96-3/1/05

NIH/NHLBI                                                         Assaf (Site PI)

The effects of hormone therapy on the development and progression of dementia (The Women’s Health Initiative Memory Study)

This study is to determine safety and efficacy of estrogen hormone replacement therapy in preventing conversion to dementia among post menopausal women. (Phase III)     

Role: Site Phase 3 clinician/co-investigator

 

22. RO1 #AG15375                                            Heindel (PI)                                          4/1/99-3/31/04

NIH/NIA                                                                                                              

Arousal, attention, and priming in Alzheimer’s disease.

This study is to understand attention related cognitive deficits and their role in memory dysfunction in patients with Alzheimer’s disease.

Role: Co-investigator (5%)

 

23. MEM-MD-10+11                                                                                                         2001-2003

Forest Laboratories, Inc.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer’s type.

This study is to determine safety and efficacy of memantine for the treatment of Alzheimer’s disease. (Phase III)

Role: Site PI

               

24. F32 #AG20008                                             Ready (PI)                                            7/1/01-6/30/03

NIH/NIA

Quality of life in cognitively impaired elderly.

This research fellowship is to understand and develop assessment instruments for quality of life in dementia.

Role: Sponsor/mentor

 

25. Ittleson Foundation                                      Ott (PI)                                                   7/16/01-2004

Memory and attentional functional MRI activation in mild cognitive impairment patients treated with donepezil.

This pilot study is to examine changes in functional MRI related to treatment with donepezil in patients with mild cognitive impairment.

Role: PI

 

26. MEM-MD-12                                                                                                               5/1/02-2003

Forest Laboratories, Inc.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of memantine in patients with mild to moderate dementia of the Alzheimer’s type.

This study is to determine safety and efficacy of memantine combined with a cholinesterase inhibitor for the treatment of Alzheimer’s disease. (Phase III)             

Role: Site PI

 

27. NER-MD-01                                                                                                                  2/4/03-2004

Forest Laboratories, Inc.

A randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of neramexane in patients with moderate to severe dementia of the Alzheimer’s type.

This study is to determine safety and efficacy of neramexane for the treatment of Alzheimer’s disease in addition to a cholinesterase inhibitor.                (Phase II)

Role: Site PI

 

28. R21 #MH62561                                           Tremont (PI)                                         12/01/01-11/30/04

A telephone intervention for dementia caregivers.

This study is to develop a telephone intervention for dementia caregivers.

Role: Consultant

 

29. U01 #AG10483                                             Thal (PI)                                                1/15/02-2/28/07

NIH/NIA/ADCS                                                  Ferris (Project director)

Assessment measures for AD primary prevention trials.

This study is to develop telephone and mail-in instruments for use in AD primary prevention trials.

Role: Site PI

 

30. U01 #AG10483                                             Thal (PI)                                                2/10/03-6/30/07

NIH/NIA/ADCS                                                  Aisen (Project director)

High dose supplements to reduce homocysteine and slow the rate of cognitive decline in Alzheimer’s disease.

This study is to determine the efficacy of folate, vitamin B6, and vitamin B12 in slowing the progression of Alzheimer’s disease. (Phase III)

Role: Site PI

 

31. Brown University Fund                                Heindel (PI)                                          6/12/03-2005

Center for Translational Brain Research

Sensory integration deficits as cognitive markers of cortical disconnection.

This study is to investigate the utility of sensory integration as a marker for early detection and progression of AD.

Role: Co-investigator

 

32. Investigator Initiated Grant                        Heindel (PI)                                          9/1/03-8/30/06

Alzheimer’s Association

Behavioral and electrophysiological investigation of semantic memory in Alzheimer’s disease.

This study is to examine the relationships between semantic deficits in Alzheimer’s disease and attention using electrophysiological event-related potentials.

Role: Co-investigator

 

33. 1RO1 #AG016335                                       Ott (PI)                                                   9/15/01-4/30/07

NIH/NIA

A longitudinal study of hazardous drivers with dementia.

This study is to define the course of driving impairment in Alzheimer’s disease and develop computerized test predictors of impaired road test performance.

Role: PI (30%)    

 

34. U01 #AG10483                                             Thal (PI)                                                9/1/02-9/1/07

NIH/NIA/ADCS                                                  Sano (Project director)

A multi-center, randomized, double-blind, placebo-controlled trial of simvastatin to slow the progression of Alzheimer’s disease.

This study is to determine the safety and efficacy of simvastatin in slowing the progression of Alzheimer’s disease. (Phase III)

Role: Site PI                                                                                                         

               

35. #EFC2946                                                                                                                      9/1/04-1/29/07

Sanofi-Synthelabo Research                                                                                           

A randomized, multicenter, double-blind, placebo-controlled, 18-moth study of the efficacy of xaliproden in patients with mild-to-moderate dementia of the Alzheimer’s type.

This study is to determine safety and efficacy of xaliproden for the treatment of Alzheimer’s disease. (Phase III)

Role: Site PI

 

36. MNI-187-01                                                  Jennings (PI)                                         11/01/07-1/7/09

Institute for Neurodegenerative Disorders

Validation of Imaging Evaluations in Individuals With Alzheimer's Disease and Healthy Subjects (VIEW-AD;

Phase 1)

This study is to evaluate multiple imaging markers for Alzheimer disease and identify SPECT ligands that most clearly distinguish Alzheimer's disease from healthy subjects of similar age.  Phase 2 will consist of a multi-site imaging study of the most promising ligand(s).

Role: Site PI

 

37. U01 #AG10483                                             Thal (PI)                                                8/10/03-1/30/09

NIH/NIA/ADCS                                                  Tariot (Project director)

A randomized, double-blind, placebo-controlled trial of valproate to attenuate the progression of Alzheimer’s disease.

This study is to determine the efficacy of valproate in preventing or delaying the emergence of agitation in patients with Alzheimer’s disease. (Phase III)

Role: Site PI

 

38. U01 #AG10483                                             Thal (PI)                                                1/01/07- 5/31/09

NIH/NIA/ADCS                                                  Quinn (Project director)

Effects of Docosahexaenoic Acid (DHA) in slowing the progression of Alzheimer’s disease.

This study is to determine the efficacy of DHA slowing the progression of cognitive and functional decline over 18 months in patients with mild to moderate Alzheimer’s disease. (Phase III)

Role: Site PI

 

39. B0401005                                                                                                                      08/14/09-2010

Pfizer

A phase 2 multicenter, double-blind placebo controlled, parallel group study of PF-04447943 in subjects with mild to moderate Alzheimer’s disease (Phase II)

This study is to determine safety and potential efficacy of PF-04447943 for the treatment of mild to moderate Alzheimer’s disease.

Role: Site PI

 

40. IIRG-07-59553                                             Martino (PI)                                          9/1/07-8/31/10

Alzheimer’s Association

Efficacy of qEEG neurocognitive training in early-stage Alzheimer’s disease.

This project investigates the efficacy of quantitative EEG neurofeedback training as a rehabilitative behavioral intervention for patients with mild cognitive impairment and Alzheimer’s disease.

Role: Consultant

 

41. #B0341002                                                    Aisen (PI)                                              1/15/08-08/30/10

ADCS/Pfizer                                                         Galasko (Project Director)

A double-blind, placebo-controlled, randomized, multicenter study evaluating the efficacy and safety of eighteen months of treatment with PF-04494700 (TTP488) in participants with mild to moderate Alzheimer's disease.

This study is to determine safety and efficacy of PF-04494700 for the treatment of Alzheimer’s disease. (Phase IIb)

Role: Site PI                                                                                                                                                         

 

42. #¹⁸F-AV-45-A17                                                                                                            June 2011- June 2012

Avid Radiopharmaceuticals

Impact of florbetapir F 18 PET on the clinical diagnosis and management of patients with progressive cognitive decline. (Phase 3b)

This study is to estimate the percentage of subjects who undergo a change in clinical diagnosis after obtaining a florbetapir F 18 PET scan.

Role: Site PI

 

43. NIH/NIA  AG036535                                  Weiner (PI)                                            9/01/09-8/31/12

NIH/NIA/ADCS                                                  Petersen and Aisen (Protocol directors)

The Alzheimer’s disease neuroimaging initiative Grand Opportunity.

This study is to develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on persons with early mild cognitive impairment.

Role: Site PI

 

44. #ELN115727-301 and 302                                                                                        12/1/07-10/31/12

Elan Pharmaceuticals, Inc.                                                                                               

A multicenter, randomized, double-blind, placebo-controlled, parallel group, efficacy and safety trial of

 bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E e4 carriers and non-

carriers. (Phase III)

This study is to determine safety and efficacy of bapineuzumab for the treatment of Alzheimer’s disease. (Phase III)

Role: Site PI

 

45. #ELN115727, WAY-203740                                                                                     1/1/11-12/31/2012

Wyeth and Janssen Pharmaceutical Companies                                                                                         

A phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter biomarker safety, and pharmacokinetic study of bapineuzumab (AAB-001) administered subcutaneously at monthly intervals in subjects with mild to moderate Alzheimer disease. (Phase II)

This study is to determine safety and efficacy of subcutaneously administered bapineuzumab for the treatment of Alzheimer’s disease. (Phase II)

Role: Site PI

 

46. 2R01 #AG016335                                        Ott (PI)                                                   5/15/07-4/30/13

NIH/NIA

Naturalistic assessment of driving in cognitively impaired elders.

This study is to define the basis of driving impairment in Alzheimer’s disease and develop computerized test predictors of impaired road test performance and driving ability in the natural home environment.

Role: PI (25%)    

 

47. 1R01 #NR010559-01                                    Tremont (PI)                                         9/28/07-5/31/13

NIH/NINR

Psychosocial telephone intervention for dementia caregivers

This study is to determine the efficacy of a telephone-based, psychosocial intervention to improve caregiver burden and depression in dementia caregivers.

Role: Co-Investigator (5%)

 

48. #160701                                                         Aisen (PI)                                              1/14/09-12/31/13

ADCS/Baxter                                                       Relkin (Project Director)

A randomized, double-blind, placebo-controlled, two dose-arm, parallel study of the safety and effectiveness of immune globulin intravenous (human), 10% (IGIV, 10%) for the treatment of mild-to-moderate Alzheimer's disease

This study is to determine safety and efficacy of IGIV for the treatment of Alzheimer’s disease. (Phase III)

Role: Site PI                                                                                                                                                         

 

49. Rhode Island Hospital                                    Ott (PI)                                                   9/01/11-10/31/13

Video intervention for the safety of cognitively impaired older drivers.

This pilot study is to examine the effects of a video event recorder intervention to enhance safe driving in people with questionable to mild dementia.

Role: Principal Investigator

 

50. Rhode Island Hospital                                     Cooper (PI)                                           2011-2014

CAFÉ:  Cognitive Assessment after Fracture in the Elderly.

This study is to examine the effect of cognitive functioning and mental health on recovery from hip fracture.

Role: Consultant

 

51.  #F-AV-45-A18

Avid Pharmaceuticals, Inc.                                                                                               1/2/13-2014

A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between florbetapir (18F) PET scan status and cognitive decline. (Phase 4)

Role: Site PI

 

52. 1 K08 HS017735-01                                    Daiello (PI)                                            6/1/09-12/31/14

AHQR

Neglected by the evidence: The intersection of medical complexity and dementia.

This is a mentored clinical science project focusing on the impact of cholinesterase inhibitor and anesthetic agents on cognitively impaired elders with complex medical illness.

Role: Mentor                                                                                       

 

53. Pfizer                                                               Snyder (PI)                                            3/01/13-2014

Detection of disease-related changes in pre-symptomatic Alzheimer’s disease.

This study is to explore several new non-invasive technologies to assist in the identification of older adults who are in the pre-symptomatic phase of Alzheimer’s disease. (Phase 1)

Role: Coinvestigator

 

54. American Heart Association                             Alosco (PI)                                            2013-2015

Cognitive impairment and driving performance in heart failure.

Predoctoral Fellowship

Role: Collaborator and Mentor

 

55.  #BP2848

F. Hoffmann-La Roche, Ltd.                                                                                            1/2/13- 2014

A multicenter, randomized, double-blind, parallel-group placebo-controlled study to investigate the efficacy and safety of RO4602522 versus placebo, used as adjunctive treatment to the acetylcholinesterase inhibitors donepezil, galantamine or rivastigmine in patients with moderately severe Alzheimer’s disease. (Phase 2B)

This study is to examine safety and efficacy a MAO-B inhibitor in patients with moderate stage Alzheimer’s disease.

Role: Site PI

 

56. #H8A-MC-LZAX

Eli Lilly and Company                                                                                                       06/24/2013-2016

Effect of solanezumab (LY20624340), an anti-amyloid beta monoclonal antibody, on the progression of Alzheimer’s disease as compared with placebo. (EXPEDITION 3 study). (Phase 3)

This study is to examine the safety, efficacy and tolerability of solanezumab in slowing the cognitive decline of mild Alzheimer’s disease.

Role: Site PI

 

57. #TRx-237-005

TauRx Therapeutics Ltd.                                                                                                   07/09/2013-2016

Randomized, double-blind, placebo-controlled, parallel-group, 18-month safety and efficacy study of Leuco-methylthioninium bis(hydromethanesulfonate) in subjects with mild Alzheimer’s disease. (Phase 3)

This study is to examine the safety, efficacy and tolerability of  Leuco-methylthioninium in the treatment of mild Alzheimer’s disease. (Phase 3)

Role: Site PI

 

58.  #221AD103

Biogen Idec MA, Inc.                                                                                                         1/6/13-2015

A randomized, double-blind, placebo-controlled multiple dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB037 in subjects with prodromal or mild Alzheimer’s disease. (Phase 1B)

This study is to examine safety, tolerability, pharmacokinetics, and pharmacodynamics of a biological agent against beta amyloid in patients with early Alzheimer’s disease.

Role: Site PI

 

59. Canadian Institute of Health Research                                                                   6/2015 – 4/2016

A collaborative international knowledge synthesis to update guidelines for determining medical fitness to operate motor vehicles.

This study is to create a knowledge synthesis and clinical guidelines on driving risks: traumatic brain injury and dementia.

Role: Project expert

 

60. AC-1204                                                                                                                        

Accera, Inc.                                                                                                                          12/-01/13-2016

26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (NOURISH AD study). (Phase 4).

This study will evaluate the effects of daily dosing of AC-1204 on cognition, activities of daily living, resource utilization, quality of life, pharmacokinetic measures and safety among participants with mild to moderate Alzheimer's Disease.

Role: Data safety monitoring board member

 

61. #1R03AG046472-01                                   Ott (PI)                                                   9/15/2014-8/31/2016

NIH/NIA

Secondary analyses and archive of naturalistic driving data in aging and dementia.

This study is to analyze naturalistic driving data obtained from older drivers with and without dementia using advanced GPS and computerized video programs that will result in a rich dataset that can then be compared to data obtained from standardized on-road tests in the same individuals.

Role: Principal investigator (8%)

 

62. #MK-8931-017

Merck Sharp & Dohme Corp.                                                                                           06/13/13-02/14/17

A Phase III, randomized, placebo-controlled, parallel-group, double-blind efficacy and safety trial of MK-8931 in subjects with mild to moderate Alzheimer’s disease. (Phase 2/3)

This study is to examine the safety, efficacy and tolerability of MK-8931 in the treatment of mild to moderate Alzheimer’s disease.

Role: Site PI

 

63. Nation’s Carelink/Univita/LTCG                   Ott (PI)                                                   10/01/06-9/30/17

Telephone screening for mild cognitive impairment.

This study is to determine the sensitivity and specificity of the Minnesota Cognitive Acuity Screen (MCAS) for mild cognitive impairment.

Role: PI

 

64.  #18F-AV-1451-A05

Avid Radiopharmaceuticals, Inc.                                                                                    1/25/14-2017

An open label, multicenter study, evaluating the safety and imaging characteristics of 18F-AV-1451 in cognitively healthy volunteers, subjects with mild cognitive impairment, and subjects with Alzheimer’s disease. (Phase 2)

This study is to compare 18F-AV-1451 imaging results in subjects with Alzheimer’s disease to subjects with mild cognitive impairment and cognitively healthy older individuals and to establish a database of cognitively healthy individuals to show the spectrum of  18F-AV-1451 imaging results in cognitively healthy individuals across a range of age strata.

Role: Site PI

 

65. #20130385                                                                                                                    4/2/2015- 2017                                          

Amgen, Inc.

A double-blind, placebo controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid lowering therapy: A study for subjects enrolled in the FOURIER trial.  Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS study).

This study evaluates change over time in neurocognitive testing in subjects receiving statin therapy in combination with evolocumab (AMG 145), compared with subjects receiving statin therapy in combination with placebo.

Role: Steering committee member

 

66.  Rhode Island Hospital                                 Ott (PI)                                                   2/1/16 – 6/30/17

Neurology Department

Pilot study of repetitive transcranial magnetic stimulation (rTMS) in the treatment of frontotemporal dementia.

This study is to determine if there is evidence of acute symptomatic cognitive benefits for rTMS when administered to patients with behavioral and progressive aphasia variants of frontotemporal dementia.

Role: Principal investigator

 

67. NIH/NIA 2U01 AG024904-06                      Weiner (PI)                                            09/30/04 – 09/15/16

NIH/NIA/ADCS                                                  Petersen and Aisen (Protocol directors)

The Alzheimer’s disease neuroimaging initiative 1, and 2.

This study is to develop improved methods which will lead to uniform standards for acquiring longitudial, multi-site MRI and PET data on persons with Alzheimer’s disease, mild cognitive impairment, and normal elderly.

Role: Site PI

 

68. Alzheimer’s Association                              Rabinovici (Study Chair)                   4/6/2015 – 12/7/17                            

CMS/ACR/ACRIN            

The Imaging Dementia – Evidence for Amyloid Scanning (IDEAS) Study

This study of patients receiving amyloid PET scan diagnostic test results for possible Alzheimer's disease seeks to understand the influence of having a positive test result on decisions to seek additional diagnostic testing or treatment and the potential cost benefits.

Role: Site PI

 

69.  Rhode Island Foundation                          Ott (PI)                                                   12/26/16 – 12/25/17

Building the Rhode Island Alzheimer’s Disease Prevention Registry

This grant is to support personnel, advertising and printing costs for expansion of the Rhode Island Alzheimer’s Disease Prevention Registry, including outreach to minorities and primary care physicians.

Role: PI

 

70. #MK-8931-019

Merck Sharp & Dohme Corp.                                                                                           06/13/14 – 01/22/2018

A randomized, placebo-controlled, parallel-group, double blind clinical trial to study the efficacy and safety of MK-8931 in subjects with amnestic mild cognitive impairment due to Alzheimer’s disease. (Phase 3)

This study is to examine the safety, efficacy and tolerability of MK-8931 in the treatment of mild cognitive impairment due to Alzheimer’s disease.

Role: Site PI

 

71. 5U01 #AG10483-21                                 Aisen (PI)                                              07/01/11 – 5/31/2018

NIH/NIA/ADCS/Univita/LTCG                           Ott (Sub-Project director)

ADCS Infrastructure Support: Rhode Island Alzheimer Prevention Registry.

This sub-project is to identify potential volunteers who would be willing to participate in upcoming early intervention and prevention trials under the sponsorship of the ADCS

Role: Site PI

 

72. #ADC-046-INI                                                                                             

NIH/NIA/ADCS                                                  Craft (PI)                                               11/01/13 – 12/31/18

Therapeutic effects of intranasally administered insulin in adults with amnestic mild cognitive impairment or mild Alzheimer’s disease. (SNIFF study). (Phase 2/3)

This study is to examine the effects of intranasally administered insulin on cognition, entorhinal cortex and hippocampal atrophy, and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment or mild Alzheimer’s disease.

Role: Site PI

 

73.  #I8D-MC-AZET                                                                                                          11/14/16 – 6/11/2018

Eli Lilly & Co.

Randomized, double-blind, placebo-controlled and delayed-start study of LY3314814 in mild Alzheimer’s disease dementia (The DAYBREAK Study).  (Phase 2/3)

This study is to test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD as compared with placebo in patients with mild AD dementia.

Role: Site PI

 

74.  #54861911ALZ2003                                  Sperling (PI)                                          12/30/16 – 6/11/18

USC Alzheimer Therapeutic Research Institute/Janssen Research and Development, LLC

A randomized, double-blind, placebo-controlled, parallel group, multicenter study investigating the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer’s dementia. (Phase 2b/3) (The EARLY Study)                        

This study is to investigate the efficacy and safety of JNJ-54861911 in subjects who are asymptomatic at risk for developing Alzheimer’s dementia.

Role: Site PI

75. #ADC-040-A4                                            Aisen (PI)

NIH/NIA/ADCS                                                  Sperling (Project Director)                  12/01/13 – 2/29/2020       

Anti-amyloid treatment in asymptomatic Alzheimer’s disease (A4 Study). (Phase 3)

This study is to determine if solanezumab, administered as an intravenous infusion at a dose of 400 mg every 4 weeks for 3 years, will slow cognitive decline as compared with placebo in subjects with preclinical Alzheimer’s disease.

Role: Site PI

 

76. # AG0045058                                            Obisesan  (PI)                                       07/10/17 – 6/30/2020

NIH/NIA

Genes, Exercise, Neurocognitive and Neurodegeneration: Community-Based Approach.

Role: Data safety monitoring board member

 

77. #221AD302                                                                                                             07/01/15 – 3/2019

Biogen MA Inc.

A phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aducanumab (BIIB037) in subjects with early Alzheimer’s disease. (EMERGE study)

This study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment in subjects with early Alzheimer’s disease.

Role: Site PI

 

78. #NPSASA-15-363629                 

Alzheimer’s Association                                   Tremont (PI)                                         9/1/15 – 10/31/19

Pilot trial of a mind-body intervention for mild cognitive impairment.

This study is to determine the preliminary efficacy of a yoga intervention for improving cognition, quality of life/emotional function, and daily living skills in individuals with mild cognitive impairment compared to the control, healthy living education.

Role: Co-investigator (3%)

 

79.  #NPSASA-15-362133

Alzheimer’s Association                                     Ott (PI)                                                   9/1/15 – 10/31/19

Video feedback intervention for cognitively impaired older drivers.

This study is to determine the efficacy of a video feedback intervention for reducing unsafe driving event frequency in older individuals with mild cognitive impairment and early Alzheimer’s disease compared to passive monitoring.

Role: Principal investigator (6%)

 

80. Seed Grant                                                Heindel (PI)                                          3/1/18 – 2/28/20

Brown University

Combined EEG and pupilometry measures of language processing as markers for early detection of Alzheimer's disease

This study exploits recent advances in cognitive neuroscience to develop novel probes that are sensitive to both the earliest cognitive changes in AD and the compensatory processes moderating these changes, and that can be utilized as a neurocognitive “stress test” for early detection of AD.

Role: Co-Investigator

 

81.  Rhode Island Foundation                          Ott (PI)                                                   7/1/18 – 6/30/19

Confronting Alzheimer’s: Primary Care and Registry Partnership Program

This project is to screen aging Rhode Islanders at risk for Alzheimer's disease and offer them ways to optimize their cognitive health through education and risk factor reduction, by partnering with primary care physicians in Rhode Island.

Role: Principal Investigator

 

82.  Global Alzheimer’s Platform Foundation             Ott (PI)                                          7/1/18 – 10/31/19

This is an infrastructure grant to support recruitment and enrollment into Alzheimer’s disease prevention and treatment clinical trials.

Role: Principal Investigator

 

83. 1R56AG053934-01                                     Mor (PI)                                                 9/1/17 – 8/31/20

NIH/NIA

Caregivers’ reactions and experience: Imaging dementia evidence for amyloid scanning (CARE-IDEAS)

This study will fill important gaps in our understanding of how informal caregivers and patients react to the results of Amyloid PET scans as part of the IDEAS study.

Role: Consultant

 

84.  #3P20GM119943-03S1                             Quesenberry (PI)                                  7/1/2019-6/30/2020

NIH/NIGMS

Retrotransposable element expression in neural stem cell senescence and aging.

This supplemental study is to examine salivary extracellular vesicles and their role in Alzheimer’s disease.

Role: Co-investigator (2%)

 

85.  Rhode Island Foundation                          Ott (PI)                                                   10/1/19-9/30/2020

Development of a web-based cognitive screening instrument.

The goal of this project is to design, develop, and validate a self-administered web-based cognitive screening application for use in the primary care setting as well as the Rhode Island Alzheimer Prevention Registry.

Role: Principal Investigator

 

86. #I5T-MC-AACG                                                                                                           11/2/17 – 2021

Eli Lilly and Company

Assessment of safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic Alzheimer’s disease (The TRAILBLAZER Study). (Phase 3)

This study is to assess the safety, tolerability and efficacy of LY3002813 alone and in combination with LY3202626 in early symptomatic Alzheimer’s disease.

Role: Site PI

 

87.  Rhode Island Foundation                          Ott (PI)                                                   10/1/20-9/30/2021

Validation of a self-administered, tablet based memory test

The goal of this project is to validate a self-administered web-based cognitive screening application for use in the primary care setting as well as the Rhode Island Alzheimer Prevention Registry.

Role: Principal Investigator

 

88. #LEARN-15-338730                                   Aisen (PI)                                              1/01/16 – 2021   

USC/Alzheimer’s Association                           Sperling (Project Director)                 

Anti-amyloid treatment in asymptomatic Alzheimer’s disease (A4 Study). (Phase 3)

This study is to determine the natural history of cognitive change in older people who lack amyoid on PET imaging.

Role: Site PI

 

89.  #R01AG056466                                          Roe (PI)                                                 8/1/17 – 5/31/22

NIH/NIA

Preclinical Alzheimer’s disease and driving

This study is to examine biomarkers of Alzheimer’s disease as predictors of driving impairment in the preclinical stage of Alzheimer’s disease.

Role: Consultant

 

90. #M15-566                                                                                                                      01/02/17 – 2021

AbbVie

A phase 2 multiple dose, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer’s disease (The AWARE Study). (Phase 2)

This study is to assess the efficacy of ABBV-8E12 in slowing disease progression (cognitive and functional impairment) in subjects with early AD as measured by the CDR-SB and to assess long term efficacy for up to 96 weeks.

Role: Site PI

 

91. NIH/NIA U19AG024904                            Weiner (PI)                                            09/15/16 - 7/31/21

NIH/NIA/ADCS                                                Petersen and Aisen (Protocol directors)

The Alzheimer’s Disease Neuroimaging Initiative 3.

This study is to develop improved methods which will lead to uniform standards for acquiring longitudinal, multi-site MRI and PET data on persons with Alzheimer’s disease, mild cognitive impairment, and normal elderly.

Role: Site PI

 

92.  BHV4157-203                                             Feldman (PI)                                        1/9/18 – 2021

ADCS/ Pharmaceuticals Holding Co. Ltd.

A seamless phase 2A-B randomized double-blind placebo-controlled trial to evaluate the efficacy and safety of BHV-4157 in patients with mild to moderate Alzheimer’s disease (The T2PROTECT AD study). (Phase 2A-B)

This study is to assess the safety, tolerability and efficacy of BHV-4157 in mild to moderate Alzheimer’s disease.

Role: Site co-PI

 

93.  #251AD201                                                                                                                  6/1/18 – 9/8/21

Biogen MA Inc.

Randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, and efficacy of BIIB092 in subjects with mild cognitive impairment due to Alzheimer’s disease or with mild Alzheimer’s disease (The TANGO study). (Phase 2)

This study is to assess the safety, tolerability and efficacy of BIIB092 in early symptomatic Alzheimer’s disease.

Role: Site PI

 

94. #R01AG058648                                           Daiello (PI)                                            4/1/2019-3/31/2024

NIH/NIA

Blood-brain barrier disruption as a biomarker for perioperative neurocognitive disorder: Cognitive recovery after elective surgery.

This study is to analyze blood-brain barrier disruption as a biomarker for the development of perioperative neurocognitive disorders after elective surgery in older adults.

Role: Co-investigator (2%)

 

95. 1R21AG064410                                           Tremont (PI)                                         6/1/19-5/31/2021               

NIH/NIA                                                              

Translating a dementia caregiver intervention into a mobile application.

The goal of this project is to adapt and test the Family Intervention: Telephone Tracking Caregiver intervention for a mobile device.

Role: Co-investigator (2%)

 

96.  5R01 AG053798-02                                   Aisen (PI)                                              5/1/19-12/3/2022

Global Alzheimer’s Platform trial-ready cohort for preclinical/prodromal Alzheimer’s disease.

This project aims to accelerate current and future secondary prevention trial enrollment through an innovative, highly efficient approach to identify, evaluate, and enroll appropriate preclinical and prodromal trial candidates, supported by a new site network with enhanced capacities for more efficient and effective conduct of AD clinical trials (The TRC-PAD Study)

Role: Site PI

 

97. #5R01AG059613-02                                   Betz  (PI)                                               05/01/19 – 02/29/24

NIH/NIA

Decision making among older adults: The AUTO study.

This study aims to aims to test the efficacy of a Driving Decision Aid in improving decision quality, determine its effects in specific subpopulations of older adults, including individuals with early Alzheimer’s disease and/or mild cognitive impairment, and identify the best settings for its future use.

Role: Data safety monitoring board chair

 

97. #BAN2401-G000-301                                                                                                 12/1/19 – 2022

Eisai, Inc.

A placebo-controlled, double-blind, parallel-group, 18-month study with an open-label extension phase to confirm safety and efficacy of BAN2401 in subjects with early Alzheimer’s disease. (The CLARITY Study) (Phase 3)

This study is to assess the safety, tolerability and efficacy of BAN2401 in early symptomatic Alzheimer’s disease.

Role: Site Co-investigator

 

98.  1R01AG061848-01                                    Aisen (PI)                                              9/30/19 - 05/31/2024

NIH/NIA and Eisai

A Placebo-Controlled, Double Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment with BAN2401 in Subjects with Preclinical Alzheimer’s Disease and Elevated Amyloid (A45 Trial) and in Subjects with Early Preclinical Alzheimer’s Disease and Intermediate Amyloid (A3 Trial).”(The AHEAD Study). (Phase 3)

This study is to assess the efficacy, safety and tolerability of BAN2401 in reducing cognitive decline and brain amyloid accumulation in people with preclinical Alzheimer’s disease.

Role: Site Co-investigator

 

99.  1 R01 AG065722-02                                  Zullo (PI)                                               10/1/20 – 9/30/2024

NIH/NIA

Medications and the risk of motor vehicle crashes in older drivers.

The objective of this project is to evaluate the effects of medications, including dose and adherence, on motor vehicle crashes in older adults.

Role: Co-investigator (2%)

 

100.  1 R01 AG068450-01                                 Alkusky (PI)                                         9/1/20 – 8/31/2023

NIH/NIA

Antidementia medication use, safety, and effectiveness among nursing home residents with Alzheimer’s disease.

The objective of this project is to examine contemporary patterns of cholinesterase inhibitor and memantine use in nursing home residents with Alzheimer’s disease, comparing long-term effectiveness and safety outcomes.

Role: Co-investigator (10%)

 

101. #221AD304                                                                                                                 4/1/20 – 2021

Biogen MA Inc.

Phase 3b open-label, multicenter, safety study of BIIB037 (aducanumab) in subjects with Alzheimer’s disease who had previously participated in the Aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. (The EMBARK study) (Phase 3b)

This open label study is being conducted to assess the long-term safety and efficacy of aducanumab in participants with Alzheimer’s disease who were actively participating in prior aducanumab clinical trials.

Role: Site Co- investigator

 

102.  #LXlOOl.Ol

Lexeo Therapeutics/Watermark                                                                                      3/12/21- 2022

A 52-Week, Multicenter, Phase I Open-label Study to Evaluate the Safety ofLXIOOI in Patients with APOE4 Homozygote Alzheimer's Disease. (The LEAD Study) (Phase 1)

This is an open label, dose-ranging study to evaluate gene therapy for patients who are APOE4 homozygotes with clinical diagnoses varying from MCI to mild or moderate dementia due to Alzheimer’s disease.

Role: DSMB member

 

103. 1 R41 AG074835-01                                 Mankodiya (PI)                                   7/1/21-6/30/22 (pending)

NIH/NIA

Development of a digital cognitive screening test to detect mild cognitive impairment and dementia in clinical settings.

This STTR Phase 1 project aims to develop and test an innovative digital cognitive screening instrument to identify mild cognitive impairment and dementia in older adults.

Role: Coinvestigator (5%)

1.  Ott BR, Libbey P, Ryter RJ, Trebbin WM. The treatment of schistosome induced glomerulonephritis. Arch Intern Med. 143:1477-1479, 1983.

2.  Ott BR, Zamani A, Kleefield J, Funkenstein H. The clinical spectrum of hemorrhagic infarction. Stroke. 17:630-37, 1986.

3.  Ott BR. Bulimia in a patient with temporal lobe epilepsy. J Neurol Neurosurgery & Psychiatry. 54:1020-21, 1991. PMCID: PMC1014638

4.  Hirano M, Ott BR, Raps EC, Minetti C, Lennihan L, Libbey NP, Bonilla E, Hays AP.  Acute quadriplegic myopathy: A complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology. 42:2082-2087, 1992.

5.  Ott BR, Lannon MC. Exacerbation of parkinsonism by tacrine. Clinical Neuropharmacology. 15:222-25, 1992. 

6.  Ott BR, Fogel BS. Measurement of depression in dementia: Self vs clinician rating. Int J Geriatr Psychiatry. 7:899-904, 1992.

7.  Farlow M, Gracon SI, Hershey LA, The Tacrine Study Group. A controlled trial of tacrine in Alzheimer’s disease. JAMA 268:2523- 2529,1992.

8.  Ott BR, Saver JL. Unilateral amnesic stroke: Six new cases and a review of the literature. Stroke. 24:1033-1042, 1993.

9.  Defusco DJ, O'Dowd P, Hokama Y, Ott BR. Coma due to ciguatera poisoning in Rhode Island. Am J Med. 95:240-243, 1993.                        
10.  Ott BR, Ellias SA, Lannon MC. Quantitative assessment of movement in Alzheimer's disease. J Geriatr Psychiatry Neurol. 8:71-75, 1995.

11. Ott BR. Leuprolide treatment of sexual aggression in a patient with dementia and the Kluver-Bucy syndrome.  Clinical Neuropharmacology. 18:443-447, 1995.

12. Rich SS, Friedman JH, Ott BR.  Risperidone versus clozapine in the treatment of psychosis in six patients with parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry. 56:556-559, 1995.

13. Ott BR. The clinical importance of gender differences in the presentation and management of Alzheimer's disease. Nursing Home Med. 4:1D-6D,1996.

14. Ott BR, Noto RB, Fogel BS. Apathy and loss of insight in Alzheimer's disease: A SPECT imaging study. J Neuropsychiatry Clin Neurosciences. 8:41-46, 1996.

15. Ott BR, Tate CA, Gordon NM, Heindel WC. Gender differences in the behavioral manifestations of Alzheimer's disease.  J Am Geriatr Soc. 44:583-587, 1996.

16. Ott BR, Lafleche G, Whelihan WM, Buongiorno GW, Albert MS, Fogel BS. Impaired awareness of deficits in Alzheimer disease. Alzheimer Disease Assoc Dis. 10:68-76, 1996.    

17. Ott BR, Thompson JA, Whelihan WM. Cognitive effects of flumazenil in patients with Alzheimer's disease. J Clin Psychopharmacology. 16:400-402, 1996.

18. Ott BR, Faberman RS, Noto RB, Rogg JM, Hough TJ, Tung GA, Spencer PK. A SPECT imaging study of MRI white matter hyperintensity in patients with degenerative dementia. Dementia Geriatr Cogn Disorders, 8:348-354,1997.

19. Ott BR, Owen NJ. Complementary and alternative medicines for Alzheimer’s disease. J Geriatr Psychiatry Neurol, 11:163-173, 1999.

20. Ott BR. Cognition and behavior in patients with Alzheimer’s disease. J Gender Specific Med, 2:63-69, 1999.

21. Paul R, Cohen R, Ott B, Zawacki T, Moser D, Davis J, Stone W. Cognitive and functional status in two subtypes of vascular dementia. Neurorehabilitation, 15(3):199-205, 2000.
   
22. Ott BR, Lapane KL, Gambassi G. Gender differences in the treatment of behavior problems in Alzheimer’s disease. Neurology, 54:427-432, 2000.

23. Fernandez HH, Lapane KL, Ott BR, Friedman JH, for the SAGE Study Group. Gender differences in the frequency and treatment of behavior problems in Parkinson’s disease. Movement Disorders, 15:490-496, 2000.

24. Ott BR, Heindel WC, Whelihan WM, Caron MD, Piatt AL, Noto RB. A SPECT imaging study of driving impairment in patients with Alzheimer’s disease. Dementia Geriatric Cogn Disorders, 11:153-160, 2000. PMCID: PMC3292192

25. Ott BR, Heindel WC, Tan Z, Noto RB. Lateralized cortical perfusion in women with Alzheimer’s disease. J Gender Specific Med, 3:29-35, 2000.

26. Ott BR, Noto RB. Sensitivity of SPECT for the diagnosis of Alzheimer’s disease. Clin  Gerontologist, 22(1):73-82, 2000.

27. Paul R, Cohen R, Moser D, Ott BR, Gordon N, Zawacki T, Bell S, Stone W. Performance on the Mattis Dementia Rating Scale among patients with vascular dementia: relationships to neuroimaging findings. J Geriatr Psychiatry Neurol, 14(1):33-6, 2001

28. Moser DJ, Cohen RA, Paul R, Paulsen JS, Ott BR, Gordon N, Bell S, Stone W. Executive function and magnetic resonance imaging subcortical hyperintensities in vascular dementia.  Neuropsych Neuropsychol Behav Neurol, 14(2):89-92, 2001

29. Paul R, Cohen R, Moser D, Ott BR, Zawacki T, Gordon N. Performance on the Hooper Visual Organizational Test in patients diagnosed with subcortical vascular dementia: Relation to naming performance. Neuropsych Neuropsychol Behav Neurol, 14(1):93-97, 2001.

30. Cohen RA, Paul RH, Zawacki TM, Sethi M, Ott BR, Moser DJ, Stone W, Noto R, Gordon N. Single photon emission computed tomography, magnetic resonance imaging hyperintensity, and cognitive impairments in patients with vascular dementia. J Neuroimaging, 11(3):253-260, 2001.

31. Ott BR, Lapane KL. Tacrine therapy is associated with reduced mortality in nursing home residents with dementia. J Am Geriatric Soc, 50:35-40, 2002.

32. Cahn-Weiner DA, Grace J, Ott BR, Fernandez HH, Friedman JH. Cognitive and behavioral features discriminate between Alzheimer’s and Parkinson’s patients. Neuropsych Neuropsychol Behav Neurol, 15(2):79-87, 2002.

33. Paul RH, Cohen RA, Moser DJ, Zawacki T, Ott BR, Gordon N, Stone W. The Global Deterioration Scale: relationships to neuropsychological performance and activities of daily living in patients with vascular dementia. J Geriatr Psychiatry Neurol, 15(1):50-54, 2002.

34. Ready RE, Ott BR, Grace J, Fernandez I. The Cornell-Brown Scale for quality of life in dementia.  Alzheimer Dis Assoc Disord, 16(2):109-115, 2002.

35. Cohen RA, Paul R, Moser D, Stone W, Ott BR, Zawacki T, Gordon N. The relationship of MRI hyperintensities and brain volume to cognitive function in vascular dementia. J Int Neuropsychol Soc, 8(6):743-752, 2002.

36. Ott BR, Belazi D, Lapane KL. Cognitive decline among female estrogen users in nursing homes. J Gerontol A Biol Sci Med, 57(9):M594-M598, 2002.   

37. Zawacki TM, Grace J, Paul RH, Moser DJ, Ott BR, Gordon N, Cohen RA. Behavioral problems as predictors of functional abilities of vascular dementia patients.  J Neuropsychiatry Clin Neurosci, 14(3):296-302,2002.   

38. Ready RE, Ott BR, Grace J. Amnestic behavior in dementia: symptoms to assist in early detection and diagnosis. J Am Geriatric Soc 51:32-37, 2003.

39. Ready RE, Grace J, Ott BR, Cahn-Weiner D. Apathy and executive dysfunction in mild cognitive impairment and Alzheimer’s disease. Am J Geriatr Psychiatry, 11(2):222-228, 2003.
                                   
40. Paul RH, Cohen RA, Moser DJ, Ott BR, Sweet L, Browndyke J, Malloy P, Garrett K. Clinical correlates of cognitive decline in vascular dementia. Cogn Behav Neurol, 16(1):40-46,2003.

41.  Ott BR, Heindel WC, Papandonatos GD. A survey of voter participation by cognitively impaired elderly patients. Neurology, 60:1546-1548,  2003.
                                   
42.  Ready RE, Ott BR. Quality of Life Measures for Dementia. Health Qual Life Outcomes, Apr 23;1(1):11, 2003. PMCID: PMC155631

43.  Sweet LH, Paul RH, Cohen RA, Moser D, Ott BR, Gordon N, Browndyke J, Shah P, Garrett KD.  Neuroimaging correlates of Dementia Rating Scale performance at baseline and 12-month follow-up among patients with vascular dementia.  J Geriatr Psych Neurol 16(4):240-244, 2003.

44.  Cahn-Weiner DA, Malloy PF, Rebok GW, Ott BR. Results of a randomized placebo-controlled study of memory training for mildly impaired Alzheimer’s disease patients. Appl Neuropsychol 10(4):215-223, 2003.

45.  Ott BR, Heindel WC, Whelihan WM, Caron MD, Piatt AL, DiCarlo MA. Maze test performance and reported driving ability in early dementia. J Geriatr Psych Neurol. 16(3):151-155, 2003. PMCID: PMC3292212

46.  Ready RE, Ott BR, Grace J. Patient vs informant perspectives of quality of life in mild cognitive impairment and Alzheimer’s disease. Int J Geriatr Psychiatry 19(3):256-265, 2004.
                               
47.  Ready RE, Ott BR, Grace J. Validity of informant reports about AD and MCI patients’memory. Alz Disease Assoc Disorders 18(1):11-16, 2004.

48.  Festa-Martino E, Ott BR, Heindel WC. Interactions between phasic alerting and exogenous attentional orienting: Effects of normal aging and Alzheimer’s disease. Neuropsychology 18(2):258-268, 2004.

49.  Garrett KD, Browndyke JN, Whelihan W, Paul RH, DiCarlo M, Moser DJ, Cohen RA, Ott BR. The neuropsychological profile of vascular cognitive impairment - no dementia: Comparisons to patients at risk for cerebrovascular disease and vascular dementia. Arch Clin Neuropsychology, 19(6):745-757, 2004.

50.  Brown LB, Ott BR. Driving and dementia: A review of the literature. J Geriatr Psychiatry Neurol 17(4):232-240, 2004. PMCID: PMC3292210

51.  Stern RA, Davis JD, Rogers BL, Smith KM, Harrington CJ, Ott BR, Jackson IM, Prange AJ. Preliminary study of the relationship between thyroid status and cognitive and neuropsychiatric functioning in euthyroid patients with Alzheimer’s dementia. Cognitive and Behavioral Neurology. 17(4):219-223, 2004.

52.  Brown LB, Ott BR, Papandonatos GD, Sui Y, Ready RE, Morris JC.  Prediction of on-road driving performance by patients with mild Alzheimer’s disease. J Am Geriatr Soc. 53(1):94-98, 2005. PMCID: PMC3292197
                           
53.  Gunstad J, Brickman AM, Paul RH, Browndyke J, Moser DJ, Ott BR, Gordon N, Cohen RA. Progressive morphometric and cognitive changes in vascular dementia. Arch Clin Neuropsychology. 20:229-241, 2005.

54.  Brown LB, Stern RA, Cahn-Weiner DA, Rogers B, Meser MA, Lannon MC, Maxwell C, Souza T, White T, Ott BR. Driving scenes test of the Neuropsychological Assessment Battery (NAB) and on-road driving performance in aging and very mild dementia. Arch Neuropsychology. 20:209-215, 2005. PMCID: PMC3292213

55.  Gasper MC, Ott BR, Lapane KL. Is donepezil therapy associated with reduced mortality in nursing home residents with dementia? Am J Geriatric Pharmacotherapy 3(1):1-7, 2005.

56.  Ott BR, Anthony D, Papandonatos GD, Sui Y, D’Abreu A, Burock J, Curtin A, Wu C-K, Morris JC. Clinician assessment of the driving competence of patients with dementia. J Am Geriatric Soc 53(5):829-833, 2005. PMCID: PMC3292185

57.  Grace J, Amick MM, D’Abreu A, Festa-Martino EK, Heindel WC, Ott BR. Neuropsychological deficits associated with driving performance in Parkinson's and Alzheimer's disease. J Int Neuropsychol Soc 11(6): 766-775, 2005. PMCID: PMC3292203

58.  Peskind E, Potkin S, Pomara N, Ott BR, McDonald S, Xie Y, Gergel I. Memantine treatment in mild to moderate Alzheimer’s disease: A randomized controlled trial. Am J Geriatr Psychiatry 14:704-715, 2006.

59.  Ready RE, Ott BR, Grace J. Insight and cognitive impairment: effects on quality of life reports from mild cognitive impairment and Alzheimer’s disease patients. Am J Alzheimers Dis Other Demen 21(4):242-248, 2006.

60.  Amick MM, D’Abreu A, Moro-de-Casillas ML, Chou KL, Ott BR. Excessive daytime sleepiness and on-road driving performance in individuals with Parkinson’s disease. J Neurological Sci 252(1):13-15, 2006.

61.  Ready RE, Ott BR, Grace J. Factor structure of patient and informant ratings on the Dementia Quality of Life Instrument. Aging Neuropsychology Cognition 14(2):144-154, 2007.
                               
62.  Ott BR, Blake LM, Sauter M, Graham SM, Bell JM. Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer’s disease. J Neurol 254(3):351-358, 2007.

63.  Bhalla RK, Papandonatos GD, Stern RA, Ott BR. Anxiety of Alzheimer’s disease patients before and after a standardized on-road driving test. Alzheimer’s & Dementia 3(1):33-39, 2007. PMCID: PMC3598633

64.  Pomara N, Ott BR, Peskind E, Resnick EM. Treatment of cognitive symptoms with memantine in mild to moderate Alzheimer's disease: Secondary analyses from a placebo-controlled randomized trial. Alzheimer Dis Assoc Disord 21(1):60-64, 2007.   

65.  Ready RE, Ott BR. Integrating patient and caregiver reports on the Cornell-Brown Quality of Life scale. Am J Alzheimer’s Dis Other Demen 22(6):528-34, 2007.

66.  Amick MM, Grace J, Ott BR.  Visual and cognitive predictors of driving safety in Parkinson’s disease patients.  Arch Clin Neuropsychol 22(8):957-67, 2007. PMCID:PMC3555123

67. Ott BR, Heindel WC, Papandonatos GD, Festa EK, Davis JD, Daiello LA, Morris JC. A longitudinal study of drivers with Alzheimer disease. Neurology 70(14):1171-1178, 2008.  PMID:18216302
               
68.  Ott BR, Festa EK, Amick M, Grace J, Davis J, Heindel WC. Computerized maze navigation and on-road performance by drivers with dementia. J Geriatr Psychiatry Neurol 21(1):18-25, 2008. PMCID: PMC3292182

69.  Smith MM, Tremont G, Ott BR. Telephone administered dementia screening. Am J Alz Disease Other Dementias 24(1):58-69, 2009.       

70. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase
inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 7(2):74-83, 2009.

71. Ott BR, Daiello LA. How does dementia affect driving in older patients? Aging Health, 6(1):77-85, 2010. PMCID: PMC2847266

72. Ott BR, Cohen RA, Gongvatana A, Okonkwo OC, Johanson CE, Stopa EG, Donahue JE, Silverberg GD. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer’s disease. J Alzheimers Dis 20(2):647-657, 2010. PMCID: PMC3078034

73. Carr D, Ott BR. The older driver with cognitive impairment: “It’s a very frustrating life.” JAMA 303(6):1632-1641, 2010. PMCID: PMC2915446

74.  Daiello LA, Ott BR, Festa EK, Friedman M, Miller LA, Heindel WC. Effects of cholinesterase inhibitors on visual attention in drivers with Alzheimer disease. J Clin Psychopharmacol. 30(3):245-51, 2010. PMCID: PMC3289132

75.  Festa, EK, Heindel WC, Ott BR.  Dual-task conditions modulate the efficiency of selective attention
mechanisms in Alzheimer’s disease. Neuropsychologia 48:3252-3261, 2010. PMCID: PMC2928570

76.  Okonkwo OC, Alosco ML, Jerskey BA, Sweet LH, Ott BR, Tremont G. Cerebral atrophy, apolipoprotein E ε4, and rate of decline in everyday function among patients with amnestic mild cognitive impairment. Alzheimers Dement. Sep;6(5):404-11, 2010. PMCID: PMC2950092

77.  Silverberg N, Ryan L, Carrillo M, Sperling R, Petersen R, Posner HB, Snyder PJ, Hilsabeck R, Gallagher M, Raber J, Rizzo A, Possin K, King J, Kaye J, Ott BR, et al. Assessment of cognition in early dementia. Alzheimers Dementia. 7(3):e60-76, 2011. PMCID:PMC3613863

78.  Carr DB, Barco PP, Wallendorf MJ, Snellgrove CA, Ott BR.  Predicting road test performance in drivers with dementia. J Am Geriatr Soc, 59:2112-2117, 2011. PMCID: PMC3228409

79.  Tremont G, Papandonatos GD, Springate B, , Huminski B, McQuiggan MD, Grace J, Frakey L, Ott BR.  Use of the telephone-administered Minnesota Cognitive Acuity Screen to detect mild cognitive impairment.  Am J Alzheimers Dis Other Demen, 26(7): 555 – 562, 2011. PMID 22127023

80.  Alosco, ML, Ott BR, Cleveland MJ, Royle K, Snyder S, Spitznagel MB, Gunstad, J. Impaired knowledge of driving laws is associated with recommended driving cessation in cognitively impaired older adults. Dement Geriatr Cogn Dis Extra, 1(1):358-365, 2012. PMCID: PMC3243640

81.  Ott BR, Papandonatos GD, Davis JD, Barco PP. Naturalistic validation of an on-road driving test of older drivers.  Human Factors, 54(4):663 – 674, 2012. PMCID:PMC3568996

82.  Davis J, Papandonatos GD, Miller LA, Hewitt SD, Festa EK, Heindel WC, Ott BR. Road test and naturalistic driving performance in healthy and cognitively impaired older adults: Does environment matter? J Am Geriatr Soc, 60(11):2056-2062, 2012. PMCID:PMC 3498523

83.  Springate BA, Tremont G, Ott BR. Predicting functional impairments in cognitively impaired older adults using the Minnesota Cognitive Acuity Screen. J Geriatr Psychiatry Neurol, 25(4):195-200, 2012. PMID 23172763

84.  Lucas-Carrasco R, Gomez-Benito J, Rejas J, Ott BR.  The Cornell-Brown Scale for Quality of Life in Dementia: Adaptation and validation into Spanish.  Alzheimer Dis Assoc Disord, 27(1):44-50, 2013. PMID 22193352

85.  Festa EK, Ott BR, Manning KJ, Davis JD, Heindel WC. Effect of cognitive status on self-regulatory driving behavior in older adults: An assessment of naturalistic driving using in-car video recordings.  J Geriatr Psychiatr Neurol, 26(1):10-18, 2013. PMID 23385363

86.  Heindel WC, Festa EK, Ott BR, Landy K, Salmon DP. Prototype learning and dissociable categorization systems in Alzheimer's disease. Neuropsychologia, 51:1699-1708, 2013. PMID:23751172

87.  Zahodne LB, Gongvatana A, Cohen RA, Ott BR, Tremont G.  Are apathy and depression independently associated with longitudinal trajectories of cortical atrophy in mild cognitive impairment?  Am J Geriatr Psychiatry, 21(11):1098-106, 2013. PMID:PMC3797189

88.  Ott BR, Davis JD, Papandonatos GD, Hewitt S, Festa EK, Heindel WC, Snellgrove CA, Carr DB. Assessment of Driving-Related Skills prediction of unsafe driving in older adults in the office setting. J Am Geriatr Soc, 61(7):1164-9, 2013.  PMID:23730836

89. Tremont G, Davis J, Papandonatos GD, Grover C, Ott BR, Fortinsky RH, Gozalo P, Bishop BS. A telephone intervention for dementia caregivers: Background, design, and baseline characteristics. Contemp Clin Trials, 36(2):338-347, 2013. PMID:23916916

90. Barco PP, Wallendorf MJ, Snellgrove CA, Ott BR,  Carr DB.  Predicting road test performance in drivers with stroke. Am J Occup Ther 68(2):221-0, 2014. PMCID:4012570

91. Manning KJ, Davis JD, Papandonatos GD, Hewitt SD, Ott BR.  Clock drawing as a screen for impaired driving in aging and dementia: Is it worth the time? Arch Clin Neuropsychol 29(1):1-6, 2014. PMCID:3897234

92. Springate BA, Tremont G, Papandonatos G, Ott BR. Screening for mild cognitive impairment using the Dementia Rating Scale-2. J Geriatr Psychiatry Neurol 27(2):139-144, 2014.  PMID:24578462

93. Snyder PJ, Lim YY, Schindler R, Ott BR, Salloway S, Daiello L, Getter C, Gordon CM, Maruff P.  Micro-dosing of scopolamine as a “cognitive stress test”: Rationale and test of a very low dose in an at-risk cohort of older adults. Alzheimers Dement, 10(2):262-7, 2014. PMID 24698030

94.  Buelow MT, Tremont G, Frakey LL, Grace J, Ott BR. Utility of the cognitive difficulties scale and association with objective test performance. Am J Alzheimers Dis Other Demen. 29(8):755-61, 2014.  PMID 24928819

95. Daniels AH, Daiello LA, Lareau CR, Robidoux KA, Luo W, Ott B, Hayda RA, Born CT. Preoperative cognitive impairment and psychological stress in hospitalized elderly hip fracture patients. Am J Orthop. 43(7):E146-52, 2014. PMID:25046191

96. Daiello LA, Gongvatana W, Dunsiger S, Cohen R, Ott BR. Association of fish oil use with preservation of brain volume and cognitive function.  Alzheimers Dement. 11(2):226-35, 2015. PMID:24954371

97. Tremont G, Davis JD, Papandonatos GD, Ott BR, Fortinsky RH, Gozalo P, Yue MS, Bryant K, Grover C, Bishop DS.  Psychosocial Telephone Intervention for Dementia Caregivers: A Randomized, Controlled Trial.  Alzheimers Dement. 11(5):541-8, 2015.  PMID:25074341

98. Alosco ML, Penn MS, Spitznagel MB, Cleveland MJ, Ott BR, Gunstad J. Reduced physical fitness patients with  heart failure as a possible risk factor for impaired driving performance. Am J Occup Ther, 69(2):1-8, 2015. PMCID:4480054

99.  Bixby KA, Davis JD, Ott BR. Comparing caregiver and clinician prediction of fitness-to-drive in people with Alzheimer’s disease. Am J Occup Ther, 69(3):1-7, 2015. PMCID:4453038

100. Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, Trikalinos TA. Do statin drugs impair cognition?  A systematic review and meta-analysis of randomized controlled trials. J Gen Int Med. 30(3):348-58, 2015. PMID:25575908 

101. Barco PP, Baum CM, Ott BR, Ice S, Johnson A, Wallendorf M, Carr DB. Driving errors in persons with dementia. J Am Geriatr Soc. 63(7):1373-80, 2015. PMID: 26140521

102.  Lim YY, Maruff P, Schindler R, Ott BR, Salloway S, Yoo D, Noto RB, Snyder PJ. Disruption of cholinergic neurotransmission unmasks Aβ-related cognitive impairment in preclinical AD. Neurobiol Aging. 36(10):2709-15, 2015. PMCID:PMC4306648

103. Papandonatos GD, Ott BR, Davis JD, Barco P, Carr DB. The clinical utility of the trail making tests as predictors of driving performance in older adults. J Am Geriatr Soc. 63(11):2358-64, 2015. PMID:26503623

104.  Tremont G, Papandonatos GD, Kelley P, Bryant K, Galioto R, Ott BR. Prediction of cognitive and functional decline with the telephone-administered Minnesota Cognitive Acuity Screen. J Am Geriatr Assoc, accepted August, 2015. 

105. Alosco ML, Penn MS, Spitznagel MB, Cleveland MJ, Ott BR, Gunstad J.  Preliminary investigation on the association between depressive symptoms and driving performance in heart failure.  Geriatrics 1(1), 2, 2016.

106. Ott BR, Pelosi M, Tremont G, Snyder PJ. A survey of knowledge and views concerning genetic and amyloid PET status disclosure. Alz Dementia: Transl Research Clin Interventions, accepted December, 2015.

106. Ott BR, Pelosi M, Tremont G, Snyder PJ. A survey of knowledge and views concerning genetic and amyloid PET status disclosure. Alzheimers Dement (N Y). 2(1):23-29, 2016. PMCID:4804344

                Comment in  AlzForum, September 12, 2016

107.  Ott BR, Davis JD, Bixby K. Video feedback intervention to enhance the safety of cognitively impaired older drivers.  Am J Occup Ther. 71(2):1-7, 2017. PMCID:5317390

108.  Roe CM, Barco PP, Head DM, Ghoshal N, Selsor N, Babulal GM, Fierberg R, Vernon EK, Shulman N, Johnson A, Fague S, Xiong C, Grant EA, Campbell A, Ott BR, Holtzman DM, Benzinger TL, Fagan AM, Carr DB, Morris JC. Amyloid imaging, cerebrospinal fluid biomarkers, and driving performance among cognitively normal individuals. Alzheimer Dis Assoc Disord. 31(1):69-72, 2017. PMCID:5085874

109. Tremont G, Davis JD, Ott BR, Galioto R, Crook C, Papandonatos G, Fortinsky RH, Gozalo P, Bishop DS. Randomized trial of the family intervention: Telephone Tracking-Caregiver for Dementia Caregivers: Use of community and healthcare resources.  J Am Geriatr Soc. 65(5):924-930, 2017. PMID:28008609.

110. Babulal GM, Traub CM, Webb M, Stout SH, Addison A, Carr DB, Ott BR, Morris JC, Roe CM. Creating a driving profile for older adults using GPS devices and naturalistic driving methodology. F1000Res. 5:2376. eCollection 2016. PMCID:5133689

111. Ott BR, Jones RN, Noto RB, Yoo DC, Snyder PJ, Bernier JN, Carr DB, Roe CM. Brain amyloid in preclinical Alzheimer’s disease is associated with increased driving risk. Alzheimers Dement (Amst). 6:136-142, 2016. eCollection 2017. PMCID:5318288

112. Skrobot OA, O’Brien J, Black S, and The VICCCS group. The Vascular Impairment of Cognition Classification Consensus Study (VICCCS). Alzheimers Dement.13:624-33, 2017. PMID:27960092.

113. Babulal GM, Stout SH, Benzinger TL, Ott BR, Carr DB, Webb M, Traub CM, Addison A, Morris JC, Warren DK, Roe CM. A naturalistic study of driving behavior in older adults and preclinical Alzheimer disease. J Appl Gerontol. Jan 1:733464817690679, 2017 [Epub ahead of print] PMID:28380718

114. Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC. Preclinical Alzheimer disease and longitudinal driving decline.  Alzheimers Dement (N Y). 3(1):74-82, 2017.  PMCID:5396459

115. Giugliano RP, Mach F, Zavitz K, Kurtz C, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Honarpour N, Waserman S, Ott BR, on behalf of the EBBINGHAUS Investigators. Design and Rationale of the EBBINGHAUS Trial: A phase 3, double-blind, placebo controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid lowering therapy – A cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol. 40(2):59-65, 2017. PMID:28207168

116. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR,  Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman, SM, Ott BR, on behalf of the EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab. New Eng J Med. 377(7):633-643, 2017. PMID:28813214

117. Festa EK, Katz AP, Ott BR, Tremont G, Heindel WC. Dissociable effects of aging and mild cognitive impairment on bottom-up audiovisual integration. J Alzheimers Dis. 59(1):155-167, 2017. PMID:28598838

118. Giugliano RP, Pedersen TR, Park J-G, De Ferrari G, Gaciog Z, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevasky E, Pineda AL, Somaratne R, Keech AC, Sever PS, Sabatine MS, on behalf of the FOURIER Investigators.  Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: A prespecified secondary analysis of the FOURIER trial. Lancet 390(10106):1962-1971, 2017. PMID:28859947

119. Margolis SA, Papandonatos GD, Tremont G, Ott BR.  Telephone-administered Minnesota Cognitive Acuity Screen predicts time to institutionalization and homecare. Int Psychogeriatr. 30(3):365-373, 2018. PMID:28942736

120. Roe CM, Babulal GM, Mishra S, Gordon BA, Stout SH, Ott BR, Carr DB, Ances BM, Morris JC, Benzinger TLS. Tau and amyloid positron emission tomography imaging predict driving performance among older adults with and without preclinical Alzheimer Disease. J Alzheimers Dis. 61(2):509-513, 2018. PMID:29171997 PMCID:5784441

121. De la Monte SM, Daiello LA, Hapel AJ, Tong M, Ott BR. Altered serum and cerebrospinal fluid inflammatory cascades in mild cognitive impairment and Alzheimer’s disease. Neuroinflamm Neurodegen (1):September 29, e1, 2017.  https://www.onjourn.com/open-access/altered-serum-and-cerebrospinal-fluid-inflammatory-cascades-in-mild-cognitive-impairment-and-alzheimers-disease-100004.pdf

122. Skrobot OA, Black S, Chen C, et al. and The VICCCS group. Progress towards standardized diagnosis of vascular cognitive impairment: guidelines from the vascular impairment of cognition classification consensus study (VICCCS). Alzheimers Dement, 14(3):280-292, 2018. PMID:29055812

123. Venkatesan U, Festa EK, Ott BR, Heindel WC. Differential contributions of selective attention and sensory integration to driving performance in healthy aging and Alzheimer’s disease. J Int Neuropsychol Soc. 24(5):486-497, 2018. PMID:29283079 PMCID:5910249

124. Wang S, Ott BR, Luo G. Detection of lane-change events in naturalistic driving videos. Intern J Pattern Recognit Artif Intell. 32(10): e1850030, 2018. https://doi.org/10.1142/S0218001418500301 PMID: 29962563 PMCID: PMC6020696 DOI: 10.1142/S0218001418500301

125.  Davis JD, Wang S, Luo G, Moharrer M, Festa EK, Bernier J, Ott BR. Detection of risky driving behaviors in the naturalistic environment in healthy older adults and mild Alzheimer's disease. Geriatrics, 3:e13, 2018. http://www.mdpi.com/2308-3417/3/2/13/pdf; PMID:29632868 PMCID:5889300

126. Pillemer S, Papandonatos GD, Crook C, Ott BR, Tremont G. The Modified Telephone-Administered Minnesota Cognitive Acuity Screen for mild cognitive impairment. J Geriatr Psychiatry Neurol. 31(3):123-128, 2018. PMID:29764279

127. Johanson C, Daiello LA, Stopa E, de la Monte S, Keane M, Ott BR.  Disrupted blood-CSF barrier to urea and creatinine in mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis Parkinsonism April 7; 8(2): e435, 2018. https://www.omicsonline.org/open-access/disrupted-bloodcsf-barrier-to-urea-and-creatinine-in-mild-cognitive-impairment-and-alzheimers-disease-2161-0460-1000435-100941.html

128. Ott BR, Jones RN, Daiello LA, de la Monte SM, Stopa EG, Johanson CE, Denby C, Grammas P. Blood-cerebrospinal fluid barrier gradients in mild cognitive impairment and Alzheimer's disease: Relationship to inflammatory cytokines and chemokines.  Front Aging Neurosci. Aug 21;10:e245, 2018. https://www.frontiersin.org/articles/10.3389/fnagi.2018.00245/full PMID:30186149

129.  ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemp Clin Trials. 2013 Nov;36(2):555-64. PMID:24113028; PMCID:PMC3919683

130.  De la Monte SM, Tong M, Daiello LA, Ott BR.  Early-stage Alzheimer's disease is associated with simultaneous systemic and central nervous system dysregulation of insulin-linked metabolic pathways. J Alzheimers Dis. 68(2):657-668, 2019.  PMID:30775986

131. Roe CM, Stout SH, Rajasekar G, Ances BM, Jones JM, Head D, Benzinger TLS, Williams MM, Davis JD, Ott BR, Warren DK, Babulal GM. A 2.5-year longitudinal assessment of naturalistic driving in preclinical Alzheimer's disease. J Alzheimers Dis. 68(4):1625-1633, 2019. PMID:30958365; PMCID:6488385

132. Margolis SA, Festa EK, Papandonatos GD, Korthauer LE, Gonsalves MA, Oberman L, Heindel WC, Ott BR. A pilot study of repetitive transcranial magnetic stimulation in primary progressive aphasia.  Brain Stimul. 12(5): 1340–1342, 2019. PMID:31186160

133.  Karpouzian-Rogers T, Heindel WC, Ott BR, Tremont G, Festa EK. Phasic alerting enhances spatial orienting in healthy aging but not in mild cognitive impairment. Neuropsychology 34(2):144-154, 2020. PMID:31464472.

134.  Moharrer M, Wang S, Davis JD, Ott BR, Luo G. Driving safety of cognitively-impaired drivers based on near collisions in naturalistic driving. J Alzheimers Dis Rep. Jan 2;4(1):1-7, 2020. PMID: 32104782 PMCID: PMC7029310 DOI: 10.3233/ADR-190159

135.  Alber J, Maruff P, Santos CY, Ott BR, Salloway SP, Yoo DC, Noto RB, Thompson LI, Goldfarb D, Song A, Snyder PJ. Disruption of cholinergic neurotransmission, within a cognitive challenge paradigm, is predictive of Aβ-related cognitive impairment in preclinical Alzheimer’s disease after a 27-month delay interval. Alzheimers Res Ther 12(1):e31, 2020.  https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00599-1  PMID: 32209123 PMCID: PMC7093953

136.  Gencer B, , Mach F, Guo J, Im K, Ruzza A, Wang H, Kurtz CE, Pederson TR, Keech AC, Ott BR, Sabatine MS, Giugliano RP, on Behalf of the FOURIER Investigators. Impact of lowering LDL-C with evolocumab on patient reported cognition from the FOURIER trial. J Am College Cardiology 75(18):2283-2293, 2020. PMID:32381158

137. Korthauer LE, Heindel WC, Lai LY, Tremont G, Ott BR, Festa EK. Impaired integration of object feature knowledge in amnestic mild cognitive impairment. Neuropsychology, 34(6):699-712, 2020. PMID:32551739  DOI: 10.1037/neu0000670

138. Moharrer M, Wang S, Dougherty BE, Cybis W, Ott BR, Davis J, Luo G. Evaluating driving safety of visually impaired bioptic drivers based on critical events in naturalistic driving. Trans Vis Sci Tech, Jul 9;9(8):e14, 2020.  https://tvst.arvojournals.org/article.aspx?articleid=2770285 PMID: 32855861 PMCID: PMC7422772 DOI: 10.1167/tvst.9.8.14

139. Margolis SA, Kelly DA, Daiello LA, Davis J, Tremont G, Pillemer S, Denby C, Ott BR.  Anticholinergic/sedative drug burden and subjective cognitive decline in older adults at risk of Alzheimer's disease.  J Gerontol ASci Med Sci. Sept 4, 2020.  PMID: 32886748 DOI: 10.1093/gerona/glaa222

140. Davis JD, Babulal GM, Papandonatos GD, Burke EM, Rosnick CB , Ott BR, Roe CM. Evaluation of naturalistic driving behavior using in-vehicle monitoring technology in preclinical and early Alzheimer's disease.  Front Psychol 11:e596257. Oct27, 2020.  https://www.frontiersin.org/articles/10.3389/fpsyg.2020.596257/full        PMID: 33192943 PMCID: PMC7653196 DOI: 10.3389/fpsyg.2020.596257

141. Ott BR, Papandonatos GD, Burke EM, Erdman D, Carr DB, Davis JD.  A video feedback intervention

for cognitively impaired older drivers. Translational Research & Clinical Interventions.  Alzheimer’s Dement. 7:e12140, 2021.  https://doi.org/10.1002/trc2.12140 2020.  PMID: 33718583 PMCID: PMC7927162 DOI: 10.1002/trc2.12140

142. Korthauer LE, Denby C, Molina D, Wanjiku J, Daiello LA, Drake J, Grill JD, Ott BR. Pilot study of an Alzheimer's disease risk assessment program in a primary care setting.  Diagnosis, Assessment & Disease Monitoring.  Alzheimer’s Dement. 13:e12157, 2021.  https://doi.org/10.1002/dad2.12157.   PMID: 33665347 PMCID: PMC7896638 DOI: 10.1002/dad2.12157

143. Drake JD, Chambers AB, Ott BR, Daiello LA. Peripheral markers of vascular endothelial dysfunction show independent but additive relationships with brain-based biomarkers in association with functional impairment in Alzheimer's disease.  J Alzheimers Dis. 80(4):1553-1565, 2021.  PMID: 33720880 DOI: 10.3233/JAD-200759.

144. Alber J, Arthur E, Goldfarb D, Drake J, Boxerman J, Silver B, Ott BR, Johnson LN, Snyder PJ. The relationship between cerebral and retinal microbleeds in Cerebral Amyloid Angiopathy (CAA): A pilot study. J Neurol Sci. 423:e117383, April 15, 2021.  https://www.jns-journal.com/article/S0022-510X%2821%2900076-9/fulltext  PMID: 33684655 DOI: 10.1016/j.jns.2021.117383

OTHER PUBLICATIONS:

1.   Ott BR, Tornabene J, Fogel BS. Deficit awareness in dementia: Relevance to the clinical diagnosis of Alzheimer's disease. In: Nicolini N, Corain B, Zatta PF, eds. Alzheimer's Disease and Related Disorders. Advances in the Biosciences. Vol. 87. New York: Pergamon Press, pp. 63-65, 1993.

2.   Ott BR. An adult with spina bifida and recurrent urinary tract infections. Neurology Reviews, 1:29, 1993.

3.   Ott BR. Diagnosis and treatment of depression in patients with dementia. The Brown University Long-Term Care Quality Letter. 5(18):1,6-7,1993.

4.   Ott BR. Huntington's disease. Rhode Island Medical Journal. 76:543-545, 1993.

5.   Ott BR. Alzheimer's disease. In: Feldmann E, ed. Current Diagnosis in Neurology.  Mosby-Year Book, Inc. 1994, pp. 173-177.

6.   DeFusco DJ, Ott BR, O'Dowd P, Hokama Y. Coma due to ciguatera poisoning in         Rhode Island (letter). Am J Med 99:106-107,1995.

7.   Ott BR. Case study: A 57-Year-old man with numbness of the chin. Neurology Reviews, 3:14, 1995.

8.   Ott BR. Non-Alzheimer dementing disorders. In: Sage JI, Mark MH, eds. Practical Neurology of the Elderly. New York, Marcel Dekker, Inc. 1996, pp. 49-114.

9.   Ott BR.  Driving and dementia: The medical perspective. Med Health/RI. 79:383-387,1996.

10. Ott BR, Grace J. Vascular dementia. Med Health/RI. 80:150-154,1997.

11. Noto RB, Ott BR. Brain SPECT scanning (letter).  J Am Geriatr Soc  46:657-658,1998.

12. Ott BR. Alzheimer's disease and other cortical dementias. In: Gilchrist JM, ed. Prognosis In Neurology.  Boston, Butterworths. 1998, pp.125-129.         

13. Abuelo DN, Walsh A, Seltzer W, Anath U, Ott BR, Geffroy G. Premature Alzheimer disease was not due to trauma: molecular biology revises diagnosis 15 years after patient’s autopsy (letter). Arch Neurol 55:1155, 1998.

14. Ott BR. Book review: Headache, by ELH Spierings, in Med Health/RI 81:279, 1998.

15. Friedman JH, Ott BR. Should risperidone be used in patients with Parkinson’s disease? (letter). J Neuropsychiatry Clin Neurosciences 10:473-475, 1998.

16. Ott BR, Mernoff ST. Driving policy issues and the physician. Med Health/RI 82:428-431, 1999.

17. Ott BR. Book review: Concepts of Alzheimer’s Disease -- Biological, Clinical, and Cultural Perspectives, ed, by PJ Whitehouse, K. Maurer, and JF Ballenger. Clinical Gerontologist 22:141-142, 2001.

18. Ott BR, Cahn-Weiner D. Gender differences in Alzheimer’s disease. Geriatric Times 2(6):23-24, 2001.

19. White T, Stern RA. Neuropsychological Assessment Battery. Reliability and validity studies, Brian Ott, contributor. Psychological Assessment Resources, Inc. Lutz, FL. 2001, 2003.    

20. Ott BR. Medical treatment of Alzheimer’s disease: Past, present, and future. Med Health/RI, 85(7):210-212, 2002.

21. Ready RE, Ott BR, Grace J. Assessment of quality of life in Alzheimer’s disease and mild cognitive impairment.  In: Research and Practice in Alzheimer’s Disease and Cognitive Decline. Vol. 7. B Vellas, M Grundman, H Feldman, LJ Fitten, B Winblad, E Giacobini, eds., Serdi, 2003.

22. Ott BR. Gender differences in the behavior of Alzheimer Disease patients. In: Alzheimer’s Disease – The Basics.  A Physician’s Guide to the Practical Management. RW Richter, BZ Richter, Eds., Humana Press, Inc.,Totowa, NJ, 2003, pp353-361.

23. Ott BR, Cahn-Weiner D. Gender differences in Alzheimer’s disease. Psychiatric Times 20(2):46-51, 2003.                                                                                                                                            

24. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of Dementia with Lewy Bodies.  Expert Opin Pharmacother, 4(11):2027-2037, 2003.

25. Heindel W, Festa-Martino A, Ott B. Retrieval from semantic memory: Differential effects of aging and Alzheimer’s disease. MIT CogNet, 2003.

26. Naor-Raz G, Heindel W, Tarr M, Ott B. Object recognition impairments in Alzheimer’s disease. MIT CogNet, 2003.

27. Paul R, Cohen RC, Ott BR, Salloway S, Eds. Vascular Dementia: Cerebrovascular Mechanisms and Clinical Management. Humana Press, Inc., Totowa, NJ, 2004.

                Chapter contributions:

                – D’Abreu A, Ott BR. Poststroke Dementia: The Role of Strategic Infarcts, 231-241.

                – Ready RE, Ott BR. Quality of Life in Vascular Dementia, 323-329.

28. Ready RE, Ott BR, Grace J. Amnestic behavior in dementia: symptoms to assist in early detection and diagnosis.  In: Research and Practice in Alzheimer’s Disease and Cognitive Decline. Vol. 7. B Vellas, M Grundman, H Feldman, LJ Fitten, B Winblad, E Giacobini, eds., Serdi, 2004.

29. Ott BR, Lapane KL. Mortality in donepezil treated patients. Letter. J Am Geriatr Soc 52(8):1412-1413, 2004.

30. Asadi-Lari M, Tamburini M, Gray D. Patients’ needs, satisfaction, and health related quality of life: Towards a comprehensive model.  BR Ott, Comment in: Health and Quality of Life Outcomes 2:32, 2004.

31. Brown LB, Ott BR, Papandonatos GD, Ready RE, Morris JC.  Who should decide driving competence? Letter. J Am Geriatr Soc 53(9):1637-1638, 2005.

32. Festa EK, Ott BR, Heindel WC. Alerting and orienting in Alzheimer’s disease: A reply. Neuropsychology 20(6):757-760, 2006.

33. Tremont G, Ott BR. Early-onset Alzheimer's disease. Op-Ed. Providence Journal, September 2, 2007.

34. Amick MM, Ott BR. Driving safety among older adults. Med Health RI, 91(5):145-147, 2008.

35. Ott BR, Heindel WC, Papandonatos GD, Festa EK, Davis JD, Daiello LA, Morris JC. A longitudinal study of drivers with Alzheimer disease. Response to letter to the editor.  Neurology 72:1109-1110, 2009.

36.  Carr DB, Ott BR. The older driver with cognitive impairment: “It’s a very frustrating life.” Response to letter to the editor, JAMA 304(7): 744-745, 2010.

37. Roth J, Ott BR, Gaitanis JN, Blum AS. The Neuroimmunology of Cortical Disease: Dementia, Epilepsy and Autoimmune Encephalopathies. In: Clinical Neuroimmunology: Multiple Sclerosis and Related Disorders.  Chapter 15, 275-285. SA Rizvi, PK Coyle, Eds., Springer Science, New York, 2011.

38.  Cohen RA, Gongvatana W, Ott BR.  Cerebrospinal fluid biomarkers of neurodegenerative and ventricular brain changes in the elderly. In: Handbook of Imaging the Alzheimer Brain, Volume 2: Advances in Alzheimer’s Disease.  J. W. Ashford, ed., IOS Press, 2011.

39.  Ott BR. The long and winding road to Alzheimer prevention.  Rhode Island Med J. 96(4):14-15, 2013.

PMID:23641444

40.  Afari ME, Blum AS, Mernoff S, Ott BR. Driving policy after seizures and unexplained syncope:

A practice guide for Rhode Island physicians, R I Med J. 91(1):40-43, 2014.  PMID:24400312

41.  Hali-Tierney AD, Ott BR.  Driving impairment in older adults. Chapter 29. In: Geriatric Neurology. AK Nair and MN Sabbagh, Eds. John Wiley & Sons, Ltd, 2014.

43.  Wing E, Ott BR. Unilateral greater occipital nerve compression causing scalp numbness. Rhode Island Med J, 98(3):34-35, 2015.  PMID:26056835

44.  Giugliano RP, Sabatine MS, Ott BR.  Cognitive Function in a Randomized Trial of Evolocumab (Letter). N Engl J Med. 377(20):1997, 2017. PMID:2914116

45.  Carr DB, Ott BR. Heart failure and fitness-to-drive. (Editorial).  J Card Fail, 26(7):564-565, 2020.  PMID:32512216  DOI:https://doi.org/10.1016/j.cardfail.2020.05.017

46. Ott BR, Daiello LA. Daiello: Remembering the importance of Alzheimer’s research during a global pandemic (Op-Ed). Providence Journal, June 17, 2020.

ELECTRONIC MEDIA PRESENTATIONS:

1.  Ott BR. A longitudinal study of drivers with Alzheimer disease.  Podcast for Neurology, Published: Mon, 31 Mar 2008. https://www.aan.com/rss/search/home/episodedetail/?item=31

2.  Ott BR. Assessing and Modifying Risks for Older Drivers. Video internet presentation for Medscape, sponsored by U.S. Department of Health and Human Services and the National Highway Traffic and Safety Administration, New York, NY, December 3, 2014. http://www.medscape.org/viewarticle/833915?src=acdmpart_nhtsa_833915

3.  Ott BR, Knopman D, Jicha G. NeuroPI: Performance Improvement in Neurology, Dementia Module. American Academy of Neurology, 2012, rev. 2016. http://tools.aan.com/practice/pip/index.cfm?event=module:info&module_id=7

4.   Ott BR. An Overview of Diseases that Lead to Cognitive Loss with an Update on Potential New Therapies.  WebCam workshop presentation for Course 4, Cognitive Dysfunction, Geriatrics Workforce Enhancement Program, University of Rhode Island, North Kingston, RI, June 29, 2017. http://web.uri.edu/rigec/about-rigec/

1975       Syracuse University, Phi Beta Kappa, Magna Cum Laude

1979       Arthur Krieger Memorial Prize in Neurology, Jefferson Medical College

1987       Greater Boston Physicians for Social Responsibility Code Blue Award, Co-recipient

1990       Fellowship, American College of Physicians

1991       Surdna Foundation Fellowship, Brown University Center for Gerontology and Health Care Research

1998       Membership, American Neurological Association

1998       Fellowship, American Academy of Neurology

1999       Honorary Brian Ott Annual Alzheimer Research Symposium founded by the RI Chapter, Alzheimer’s Association; recognized  by Lieutenant Governor’s Office, State of RI

1999       Excellence in Teaching Award, Brown University Geriatric Psychiatry Program   

2002-      Who’s Who in Medicine and Healthcare, 4th edition

2003-      Who’s Who in America, 58th edition

2004-      Best Doctors in America, Neurology

2011-      Adjunct Professor of Pharmacy Practice, University of Rhode Island

2013       Appointment by Governor Lincoln Chafee to the Rhode Island Advisory Commission on Aging

2013       Fellowship, American Neurological Association

2013       Jerome Ely Award for article of the year, Human Factors  

2014       Dean’s Excellence in Teaching Award, Alpert Medical School of Brown University

2017       Adjunct Professor of Neuroscience, University of Rhode Island   

2018       Positive Champion of the Learning Environment, Alpert Medical School, Brown University  

2018       Visiting Professor, Southern Illinois University       

2018       Elise M. Coletta Education Leadership Award, Rhode Island Chapter, American Academy of Family Physicians 

2018       Milton Hamolsky Lifetime Achievement Award, Rhode Island Chapter, American College of Physicians  

2018       Pursuit of Excellence speaker, Rhode Island Hospital

2019       Appointment by Governor Gina Raimondo to the Advisory Council on Alzheimer’s Disease Research and Treatment

ACADEMIC APPOINTMENTS:

1982-1985    Clinical Fellow in Neurology, Harvard University Medical School
1989-1996    Assistant Professor, Department of Clinical Neurosciences, Brown University Medical
                     School
1996-2002    Associate Professor, Department of Clinical Neurosciences, Brown University Medical
                     School
2002-2009    Professor, Department of Clinical Neurosciences, Brown University Medical School
2009             Professor, Department of Neurology, Warren Alpert Medical School, Brown University
2011             Adjunct Professor of Pharmacy Practice, University of Rhode Island                                                                    2017             Adjunct Professor of Neuroscience, University of Rhode Island

HOSPITAL APPOINTMENTS:

1985-1989    Active Staff, Addison Gilbert Hospital, Gloucester, MA
1985-1989    Courtesy Staff, Hunt Memorial Hospital, Danvers, MA
1985-1989    Active Staff, Beverly Hospital, Beverly, MA
1989-1990    Associate Active Staff, Roger Williams Medical Center, Providence, RI
1990-1992    Consultant Staff, U.E. Zambarano Memorial Hospital, Wallum Lake, RI
1990-1996    Active Staff, Roger Williams Medical Center   
1997-2005    Courtesy Staff, Roger Williams Medical Center
1996-2005    Active staff, Memorial Hospital of Rhode Island, Pawtucket, RI
1994-2005    Consultant Staff, Rhode Island Hospital, Providence, RI
2005-2009    Consultant Staff, Memorial Hospital of Rhode Island                                                                                           2009-2018    Courtesy Staff, Memorial Hospital of Rhode Island
2010-2019    Consulting Staff, Women’s and Infants Hospital, Providence, RI                                                                                      2000             Consultant Staff, Miriam Hospital, Providence, RI
2005             Active Staff, Rhode Island Hospital  

UNIVERSITY TEACHING ROLES:

1984-1985    Introductory lectures to Harvard medical students on neurology rotation, Brigham & Women's Hospital

1989-1996    BioMed 301 Clerkship in Internal Medicine
                     Introductory lectures and group case discussions in neurology for third year Brown medical students rotating on             medical clerkship, Roger Williams Medical Center
                     1989-1995        One session every three months,
                     1995-1996        Outpatient general neurology clerkship. 

1989-2005    BioMed 304F Clerkship in Consultative Neurology
                     Clinical teaching rotation for medical students, Roger Williams Medical Center and Memorial  Hospital
 
1990-2006    BioMed 262 Neurosciences Pathophysiology lectures           

                      Revised and improved syllabus and presented lectures.
                      Toxic and Metabolic Disorders of the CNS

                      Instituted new syllabus and presented lectures.
                      Infections of the CNS

                      Revised and improved syllabus and presented lectures.
                      Aging and Dementia

1990-2006    BioMed 262 Neurosciences Pathophysiology  Small Group Laboratory Session leader

                      Four to five sessions each year, 10-12 students

1993              With assistance of Dr. Sydney Louis, designed and produced a self study and assessment computer program in           Behavioral Neurology for medical students and housestaff.
                   
1993-2005    BioMed 315F Clerkship in Adult Ambulatory Medicine (Neurology)

                     For  Brown medical students, Roger Williams Medical Center and Memorial  Hospital.
                     One half-day weekly over six months with one student in general neurology outpatient practice setting

                     1998-2005    Clerkship leader

1993-            Clinical supervisor for graduate student research projects in dementia, Brown University Department of                  Psychology, at Roger Williams, Memorial and Rhode Island Hospitals

1994             Independent Clerkship in Advanced Physical Diagnosis for third year Brown medical student

1994-            Instituted new syllabi and presented lectures for University of Rhode Island course PHP 561/562, Advanced Human Pathophysiology I and II and PHP/BPS 312, Foundations of Human Disease I and II

                     Pathophysiology of Pain
       
                     Aging and Dementia

                    Stroke: Ischemic and Hemorrhagic

1995            Brown University Summer FOCUS Program course, So You Think You Want to be a Doctor: An Introduction to Medicine, lecture to high school students

                     The Neurological Examination

1997-2005    BioMed 373-374 Introduction to Clinical Medicine lecture to second year Brown medical students   
                     The Neurological Examination

1998-2000   University of Rhode Island Pharmacy Program course, Advanced Human Pathophysiology for Practitioners lectures

                    Pathophysiology of Pain
       
                    Alzheimer's Disease

                   Cerebrovascular Disease

1998-         Website administrator, Department of Neurology, Brown University

2005          BioMed 372 Epidemiology for the Practice of Medicine small group laboratory leader
                  Two sessions each year, 12-15 students

2007          Brown University PHP 2210 Epidemiology of Chronic Disease
                                           
                  Alzheimer’s Disease lecture and discussion session

2008-        BIOL 903 So You Want To Be a Doctor

                 Case and career discussions; office shadowing experience: High school seniors

2010-        BIOL 3790 Aging and Dementia
                 Course leader: elective for fourth year medical students

2011-        BIOL 3795 Elective Clerkship in Neurology
       
                  Clerkship working group leader and faculty member

2012-        Roger Williams University Law School: Planning for the Elderly Client and Introduction to Elder Law courses

                 Lecture and discussion session

HOSPITAL TEACHING ROLES:

1989-2005    Two month required clinical rotation in consultative neurology for first year psychiatry residents from Butler Hospital, at Roger Williams Hospital & Memorial Hospitals.

1989-2005    Noon lectures, consultation rounds, and neurology elective for medical housestaff, one out of every two to three months, Roger Williams & Memorial Hospitals.

1990-1999    Teaching attending sessions, twice weekly for one month per year, for neurology and medical housestaff and medical students, Rhode Island Hospital.
   
1990-2005     Supervisor/mentor, two month required clinical rotation in consultative neurology for third year  neurology residents, Roger Williams & Memorial Hospitals.
   
1990-             Alzheimer's disease and memory disorders specialty outpatient teaching clinic for third year neurology residents, medical housestaff, and students, one morning per week year round, Roger Williams, Memorial, and Rhode Island Hospitals
       
1992-             Workshop and journal club lectures in dementia diagnosis and treatment to psychiatry residents at Butler Hospital.

1993-1999     Internal Medicine Board Examination Review in Neurology for third year medical residents, Roger Williams & Memorial Hospitals.  Three hour neurology review session, annual.

1994-1996     Director of Neurology Education for the Roger Williams Hospital Internal Medicine Residency. 
                      Compiled curriculum for neurology education, 1994.

1996-2005     Lectures and weekly case discussions for internal medicine residents, family practice residents, and Brown medical students, Memorial Hospital
       
1998-             Supervisor/mentor, memory disorder clinic outpatient teaching rotation for Brown University Geriatric Psychiatry Fellowship Training Program

1999-              Internship faculty member, Brown University Clinical Psychology Training Consortium
2004-              Research supervisor
       
2000-             Supervisor/mentor, memory disorder clinic outpatient teaching rotation for Brown University
                      Geriatric Medicine Fellowship Training Program
       
2001-2003     F-32 research fellowship co-sponsor (Rebecca Reddy)
       
2002-2005     Director, Brown University Geriatric Neurology Fellowship
       
2001-2008     Steering committee member, mentor, and lecturer for the Brown University T-32 Dementia Research Fellowship program

2009-2014      K-08 research career award primary mentor (Lori Daiello)   

2013-2015      Predoctoral Fellowship award mentor (Michael Alosco)   

2020-2025      K-23 research career award mentor (Laura Korthauer, PhD)

2015-              Director, Rhode Island Hospital and Brown University Aging and Dementia Fellowship

                          2016-2018            Seth Margolis, PhD

                          2017-2018            Jonathan Drake, MD

                          2018-2020            Laura Korthauer, PhD

                          2020-2021            Jamie Bass, DO

                          2020-2022            Deirdre O’Shea, PhD